Chiropractors in Estacada, OR Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Dr. Jonathan Rhue, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 437 Ne Main St, Estacada, OR 97023 Phone: 503-630-4037 Fax: 503-630-5636 |
 Oregon Trail Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 437 Ne Main St, Estacada, OR 97023 Phone: 503-630-4037 Fax: 503-630-5636 |
Michael T Malone Iii, D.C. Chiropractor - Sports Physician Medicare: Not Enrolled in Medicare Practice Location: 437 Ne Main St, Estacada, OR 97023 Phone: 503-630-4037 Fax: 503-630-5636 |
 Rhea Marie Putnam, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 437 Ne Main St, Estacada, OR 97023 Phone: 503-630-4037 |
News Archive
Key mechanism to emergence of deadly strep bacteria discovered
The incidence of serious strep infections has risen dramatically in the last three decades, and this increase is largely attributed to the spread around the globe of a single strain of strep known as the invasive M1T1 clone.
Athletes and non-athletes gather at TCS New York City Marathon
Well known for its culture, theater, and cuisine, New York is also one of the 25 healthiest cities in the United States. It's this fitness side that will be on show this weekend with the TCS New York City Marathon.
Targeted drug shows promising activity in kidney cancer patients with brain metastases
A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.
AMA campaign to stop parents smoking near babies and children
The bib giveaway, launched at King Edward Memorial Hospital today, is the centrepiece of a campaign to encourage parents not to smoke near their baby or children.
Provectus' PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting
Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.
› Verified 7 days ago